|View printer-friendly version|
Charles River intends to use the net proceeds of the borrowings under
the credit facilities to fund the cash consideration and other amounts
payable, including the repayment of certain outstanding indebtedness,
for its previously announced acquisition of
Charles River is issuing the notes as a strategic complement to our long-term capital structure, and intends to use the net proceeds of the offering of the notes to repay borrowings under the refinanced credit facilities.
The notes have not been, and will not be, registered under the
Securities Act of 1933, as amended (the “Securities Act”), or under the
securities laws of any other jurisdiction. Unless they are registered,
the notes may be offered only in transactions that are exempt from
registration under the Securities Act and applicable state securities
laws. The notes will be offered only to persons reasonably believed to
be qualified institutional buyers under Rule 144A under the Securities
Act and to non-U.S. persons outside
This press release does not constitute an offer to sell or a solicitation of an offer to buy the notes, nor shall there be any sale of the notes in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Caution Concerning Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words such as
“anticipate,” “believe,” “expect,” “intend,” “will,” “may,” “estimate,”
“plan,” “outlook,” and “project” and other similar expressions that
predict or indicate future events or trends or that are not statements
of historical matters. Forward-looking statements include statements in
this news release regarding the potential securities offering, the
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations